<DOC>
	<DOC>NCT01505530</DOC>
	<brief_summary>This phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial in participants with locally advanced/inoperable or metastatic pancreatic cancer, and will investigate 2 different doses of LY2495655 in combination with standard of care chemotherapy.</brief_summary>
	<brief_title>A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Inclusion: Unresectable or metastatic pancreas cancer; participants with previous radical surgery for pancreas cancer are eligible after progression is documented Participants may have received previous adjuvant treatment with gemcitabine with or without radiotherapy for pancreas cancer ECOG (Eastern Cooperative Oncology Group) Performance status â‰¤ 2 Adequate organ function Have an estimated life expectancy of at least 12 weeks and in the judgment of the investigator, will be able to complete at least 2 cycles of treatment Ability to perform the indicated functional performance measures at baseline Exclusion: Prior systemic therapy for unresectable/metastatic pancreas cancer Any medical or psychiatric condition, orthopedic or neuromuscular conditions that could limit participation or confound study results Currently taking medications that are considered both muscle building and performance enhancing (for example, androgen therapies, or anabolic steroids)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>